DEA Registration for State Medical Marijuana Licensees

The New Federal Registration Pathway for State Medical Marijuana Licensees 

The Department of Justice has now done more than gesture toward federal accommodation of state medical cannabis programs. In a final rule published and effective April 28, 2026, following an April 22, 2026 Attorney General order, DOJ and DEA placed qualifying medical marijuana products into Schedule III and established an expedited DEA registration process., the Acting Attorney General placed FDA-approved products containing marijuana, as well as marijuana, marijuana extracts, and naturally derived delta-9-tetrahydrocannabinols contained in products subject to a qualifying state medical marijuana license, into Schedule III of the Controlled Substances Act. At the same time, the order amended DEA’s regulations to establish an expedited registration process under 21 C.F.R. part 1301 for entities holding state medical marijuana licenses and seeking to manufacture, distribute, or dispense marijuana or marijuana-containing products for medical purposes. Schedules of Controlled Substances: Rescheduling of Food and Drug Administration Approved Products Containing Marijuana and Products Containing Marijuana Subject to a Qualifying State-Issued License FromSchedule I to Schedule III; Corresponding Change to Permit Requirements 1–2, 27–33 (Acting Att’y Gen. Apr. 22, 2026).  

For businesses operating in state medical marijuana programs, that is a material legal development. It creates not merely a policy preference, but a new regulatory lane. The question is no longer whether federal law may someday recognize such operators. For qualifying state medical marijuana licensees, the federal government has now written a registration pathway into the regulations themselves. Id. at 27–31.  

The immediate issues are practical. What exactly has been created? What must an applicant show? How is the application filed? And what should a serious operator be doing now? 

This page addresses the DEA registration pathway for qualifying state medical marijuana licensees. It does not address the broader proposed rescheduling of marijuana, which remains subject to a separate DEA administrative hearing scheduled to begin June 29, 2026.

For a broader overview of the bifurcated federal rescheduling process, 280E relief, adult-use exposure, and pending litigation risk, see Federal Cannabis Rescheduling & Schedule III Counsel.

What the Final Order Actually Does 

The order rests on 21 U.S.C. § 811(d)(1), which authorizes scheduling action where control is required to carry out the United States’ obligations under international narcotics treaties, including the Single Convention on Narcotic Drugs (1961). The order explains that the United States must maintain a medical and scientific control structure for marijuana consistent with those treaty obligations, including licensing, control of manufacture and distribution, import and export restrictions, prescriptions for dispensing, recordkeeping, and other regulatory measures. Final Order at 2–9, 24–25.  

Within that framework, the Acting Attorney General concluded that marijuana contained in FDA-approved products, as well as marijuana and certain related compounds contained in products subject to a state medical marijuana license, should be placed in Schedule III. The order makes equally clear, however, that unlicensed bulk marijuana, marijuana extract, and delta-9-THC material used to make FDA-approved products remain in Schedule I, and that synthetically derived tetrahydrocannabinols are not covered by this action. Id. at 14–17, 31–33.  

This is therefore not general legalization, nor even blanket Schedule III treatment for all marijuana. It is a selective medical reclassification coupled with a federal registration regime designed to integrate qualifying state medical operators into a treaty-compliant controlled-substances framework. Id. at 14–17, 21–23.  

The New Expedited DEA Registration Process 

The most commercially significant feature of the order appears in the regulatory amendments to 21 C.F.R. § 1301.13. New subsection (k), titled “Medical marijuana registrations,” directs that “[t]he Administration shall establish an expedited review process” for entities holding state medical marijuana licenses and seeking registration as a marijuana manufacturer, distributor, or dispenser. 21 C.F.R. § 1301.13(k) (as amended Apr. 22, 2026); Final Order at 28.  

The regulation further provides that applicants must submit the applicable DEA form or forms, together with proof of a state medical marijuana license in the form specified by the Administrator. Id. at 28.  

That matters for two reasons. First, the existence of the pathway is no longer aspirational. It is now codified. Second, the regulation expressly ties eligibility to an underlying state medical marijuana license and channels the application through the familiar DEA registration framework rather than some entirely new licensing apparatus. Id. at 27–28.  

Who Appears Eligible 

The order defines a “state medical marijuana license” as a license issued by a state, the District of Columbia, or a federal territorial entity authorizing the holder to manufacture, distribute, and/or dispense marijuana or products containing marijuana for medical purposes. Final Order at 27.  

That definition is not merely descriptive. It does substantial work. The new rule provides that, for purposes of the applicable public-interest provisions, a qualifying state medical marijuana license “shall constitute conclusive evidence that the applicant is authorized under state law to engage in the activity for which registration is sought.” Id. at 29.  

In practical terms, the threshold eligibility inquiry is straightforward: does the business hold a qualifying state-issued medical marijuana license, and does the requested federal registration correspond to the activity authorized by that state license? If the answer is no, the expedited pathway likely is unavailable. If the answer is yes, the applicant enters the process with a significant evidentiary advantage, because the rule itself gives the state license conclusive effect on the question of state-law authorization. Id. at 28–29.  

What Must the Applicant Show 

The rule is accommodating, but it is not casual. It states that the Administrator shall register an applicant under the new subsection unless the Administrator determines that registration would be inconsistent with the public interest, taking into account the factors set forth in 21 U.S.C. § 823(e), (g), as applicable, together with the requirements of the Single Convention and any quota requirement. Final Order at 28.  

The order also states, however, that, in general, registration of an applicant operating under a state-law regime that contains robust diversion protections, recordkeeping and reporting requirements, and safety and inspection measures will not be inconsistent with the public interest so long as registration is consistent with the Single Convention. Id. at 21–22, 28.  

A serious application should therefore be built to demonstrate at least five things. 

First, the applicant must show possession of a valid qualifying state medical marijuana license that matches the registration sought. Because the federal registration may not exceed the scope of the underlying state license, imprecision here is dangerous. The rule expressly provides that a registration issued under the subsection shall not exceed the scope of the holder’s state medical marijuana license. Id. at 29.  

Second, the applicant should present the state regulatory environment as one that already satisfies the federal concerns emphasized in the order: diversion prevention, reporting, inspections, product safety, and lawful medical distribution. The order repeatedly stresses that mature state medical systems have developed robust infrastructure serving the same public-interest objectives that underlie the CSA’s registration framework. Id. at 20–22.  

Third, the applicant should be prepared to show that its operations are medical, not adult-use. The regulation is explicit that registrations under this subpart “do not authorize the manufacture, distribution, dispensing, or use of marijuana or products containing marijuana for non-medical purposes.” Id. at 29.  

Fourth, the applicant should be able to present a credible compliance architecture. Although the rule is notably deferential to state systems, federal registration still places the business within a federal controlled-substances framework. The applicant should expect scrutiny concerning records, inventory, chain of custody, authorized personnel, site controls, and inspection readiness. Id. at21–22, 29–31.  

Fifth, manufacturers in particular must reckon with treaty-driven structural requirements. The order provides that all registered manufacturers must establish a nominal price for their marijuana crops; the Administration then purchases the crops and resells them back to the entity, or a related subsidiary, at the same price plus an administrative fee. Registered manufacturers must also store crops in a facility to which the Administration maintains access until that transaction is complete, and the registration must specify the areas in which cultivation is permitted. Id. at 22, 30.  

That is not incidental. It is the framework through which treaty compliance is being achieved. 

What the Registration Permits 

The regulation sets out three registration types. 

A registered marijuana manufacturer may cultivate, produce, process, package, label, and transfer marijuana and marijuana-containing products to registered distributors or other registered manufacturers, subject to the limits of its state license. A registered distributor may receive marijuana and marijuana-containing products from registered manufacturers and transfer them to registered dispensers or other registered distributors, again subject to the limits of its state license. A registered dispenser may dispense marijuana and marijuana-containing products to individuals authorized by state law to possess them for medical purposes, also subject to the limits of its state license. Id. at 28–29.  

Those permissions are meaningful. They also underscore that the federal government is not adopting the commercial grammar of the adult-use market. It is recognizing a bounded medical channel. 

How the Application Is Filed 

The final order does not create a new numbered DEA form in the regulatory text. Instead, it requires submission of the “applicable DEA form or forms,” together with proof of state medical marijuana licensure in the form specified by the Administrator. Id. at 28.  

That means the application will proceed through the existing DEA registration machinery, supplemented by whatever Administrator-issued instructions govern proof of licensure and related submissions. The regulation is clear on the legal pathway, even if DEA’s operational guidance may continue to develop in the near term. Id. at 28–30.  

The prudent course is not to assume that form completion alone resolves the matter. The application should be treated as a lawyer-built regulatory presentation that aligns the state license, the federal registration category, the applicant’s operational model, and the public-interest and treaty considerations embedded in the order. 

The Critical 60-Day Window 

The rule contains a timing provision of unusual practical importance. It states that the Administrator shall make every effort to process applications submitted within sixty days of publication of the rule in the Federal Register within six months. More significantly, it provides that any applicant submitting an application within that sixty-day period “may engage in the manufacture, distribution, and/or dispensing of marijuana or marijuana products for medical purposes in conformity with a state-issued license during the pendency of the application.” Id. at 30.  

That is the provision likely to drive immediate demand. 

It also carries two obvious implications. First, the relevant trigger is publication in the Federal Register, not merely agency press coverage or secondary reporting. Second, the benefit attaches to timelyfiling and conformity with the state-issued medical license. A business that delays, files carelessly, or cannot demonstrate clean state-law compliance may lose the very interim protection that makes this pathway so commercially significant. Id. at 30.  

The Rule’s Deference to State Medical Systems 

One of the more striking features of the order is the degree to which it incorporates, rather than supplants, state medical regulatory systems. 

The rule states that DEA should require only such reports, records, and order forms as the Administrator concludes are necessary to comply with federal statutory and treaty obligations, and that the Administrator shall accept state-required reports, records, and forms to the maximum extent permissible. It also provides that state-authorized certifications and similar documents may be sufficient for medical dispensing; that registrants may rely on state-law labeling, packaging, disposal, and physical-security requirements in lieu of otherwise applicable federal rules, subject to limited qualifications; and that the special federal warning required by 21 U.S.C. § 825(c) must still appear where applicable. Id. at 21–22, 29–31.  

This is not a trivial accommodation. It reflects a deliberate federal judgment that existing state medical systems can be incorporated into a federal registration framework without displacing them wholesale. Id. at 21–22.  

The State License Remains the Keystone 

That accommodation, however, has a corresponding discipline. The order provides that if the state medical marijuana license is suspended, revoked, or expires, the DEA registration issued under the subsection is automatically suspended. Id. at 29.  

Federal authorization therefore tracks state authorization. That feature should affect not only how an application is prepared, but how the business thinks about ongoing state compliance. A shaky state license is not merely a local problem; under this rule, it is also a federal vulnerability. 

Section 280E 

The tax implications are explicit. The Acting Attorney General states that, as a consequence of the rule, holders of state medical marijuana licenses “will no longer be subject to the deduction disallowance imposed by Section 280E,” because that provision applies only to trafficking in controlled substances in Schedule I or II. Id. at 17.  

The order goes further. It states that the Administrator “encourages the Secretary of the Treasury to consider providing retrospective relief from Section 280E liability” for tax years in which a state medical marijuana licensee operated under such a license. Id. at 23.  

That does not itself grant retroactive tax relief, and the order expressly disclaims making any determination regarding federal tax liability. Id. at 17, 23. But it does make clear that the federal government now understands the tax consequence of its scheduling action and has affirmatively invited Treasury to consider relief for prior years. For many operators, that will not be a peripheral issue. It may be one of the principal reasons to move quickly. 

The Bottom Line 

The final order does not normalize cannabis generally. It does something narrower and, for the right operators, more useful. It creates a federally recognized, expedited registration pathway for entities holding qualifying state medical marijuana licenses, integrates those entities into a Schedule III medical channel, gives conclusive evidentiary effect to state licensure on the question of state-law authorization, permits timely applicants to operate during the pendency of their applications, and expressly removes qualifying licensees from the reach of § 280E going forward. Final Order at 17, 21–23, 28–30.  

For businesses that may qualify, this is not the moment for vague optimism. It is the moment for careful filing strategy. 

Disclaimer 

This article is provided for general informational purposes only and does not constitute legal, tax, or regulatory advice. The final order discussed here is a recent development, and agency implementation guidance may continue to evolve. The application of the order, DEA registration requirements, and related tax and regulatory consequences depends on the facts of a particular business, product, license, and jurisdiction. Readers should consult qualified counsel and tax professionals before acting on any information discussed here. Viewing this article does not create an attorney-client relationship with Joseph A. Bondy, PLLC. 

About Joseph A. Bondy, PLLC 

Joseph A. Bondy, PLLC advises cannabis businesses, investors, and stakeholders on cannabis business law, regulatory compliance, and the evolving federal legal framework governing the industry. The firm is available to assist qualifying medical cannabis businesses in evaluating eligibility for, preparing, and navigating the new expedited DEA registration pathway, including state-license alignment, application strategy, compliance presentation, and related tax and regulatory issues. 

To inquire about representation or consultation, please contact Joseph A. Bondy, PLLC through the firm’s website.